profit from every $100 of sales.
$0$100
Design Therapeutics
$10.58-1.76% today
+39.0% in 1 year
1-year low $7.061-year high $15.94
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Design Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$69.8 million of profit last year.
SalesProfit
Design Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Design Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads Design Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -68 | -78 | -62 | -79 | |
| -67 | -78 | -62 | -79 | |
| -63 | -67 | -50 | -70 | |
| -1.14 | -1.19 | -0.88 | -1.22 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 341 | 290 | 252 | 226 |
| Cash | 27 | 21 | 23 | 17 |
| Total debt | 4 | 3 | 2 | 2 |
| Total liabilities | 14 | 12 | 10 | 14 |
| 327 | 278 | 242 | 213 | |
| 56 | 56 | 57 | 57 | |
| -16.1% | -22.0% | -20.2% | -29.3% | |
| -19.3% | -24.1% | -20.5% | -32.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -51 | -59 | -43 | -54 | |
| 1 | 0 | 0 | 0 | |
| -52 | -59 | -43 | -55 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 11 | 13 | 13 | 15 |
Valuation
- –
- –
- –
- 4.0×
- –
- –
- –
- -8.1%
- -10.3%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -35.7%
- -21.0%
- -33.1%
- -30.3%
- -35.8%
- –
Growth
- –
- –
- −25.6%
- –
- +5.7%
Financial health
- 0.1×
- 0.01
- 1.2%
- –
- 22.28
- 22.28
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 13%of 952
Bottom 20%of 883
Bottom 13%of 985
What analysts expect
- Average price target
- $17.50
- Range
- $14.00 – $21.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 28, 2026 | -0.29 | -0.36 | +19.4% |
| Mar 9, 2026 | -0.27 | -0.38 | +28.9% |
| Nov 5, 2025 | -0.30 | -0.34 | +11.8% |
| Aug 7, 2025 | -0.34 | -0.32 | −6.3% |
| May 7, 2025 | -0.31 | -0.28 | −10.7% |
| Mar 10, 2025 | -0.24 | -0.28 | +14.3% |
| Nov 7, 2024 | -0.23 | -0.26 | +11.5% |
| Aug 5, 2024 | -0.21 | -0.25 | +16.0% |
News
Jacobs wins $2.1B design contract for New Zealand highwaySeeking Alpha · Nov 5, 2026Alnylam downgraded at Bernstein on TRITON-CM trial designSeeking Alpha · Oct 30, 2026NuScale Power Trades Below $6 With the Only NRC-Certified Small Modular Reactor Design. Here's Why That Still Isn't Enough.Yahoo Finance · Oct 25, 2026Cadence Design Systems (CDNS) Stock Looks Fully Valued Despite AI HopesYahoo Finance · Oct 24, 2026Dassault Systèmes and Vertiv Team to Accelerate AI Factory Design and DeploymentYahoo Finance · Oct 22, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
22No pass
Benjamin Graham
40No pass
Philip Fisher
32No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
27No pass
Terry Smith
24No pass
Questions about Design Therapeutics
Is Design Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Design Therapeutics AI analysis
What does Design Therapeutics do?
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. It is in Biotechnology.
Does Design Therapeutics pay a dividend?
No. Design Therapeutics does not pay a dividend at the moment.
Is Design Therapeutics stock halal?
Questionable. Design Therapeutics sits in a grey zone: its cash and confirmed interest-bearing investments are 32% of its market value, between 30% and 33%. How we check
How has Design Therapeutics stock done over the past year?
Up 39.0% over the past twelve months, to $10.58. It traded between $7.06 and $15.94 and is 33.6% below its high.
Who are Design Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Design Therapeutics's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.